ArticleProceedings of the National Academy of Sciences of the United States of America2015

AAV9 delivering a modified human Mullerian inhibiting substance as a gene therapy in patient-derived xenografts of ovarian cancer.

David Pépin et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.